Yajamanam Badrinath
Navi Mumbai, MH, India
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Detecting hypodiploidy with endoreduplication and masked hypodiploidy in B-cell acute lymphoblastic leukemia using multicolor flow cytometry.
Journal: Cytometry. Part B, Clinical cytometry
Published: June 26, 2021
Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion.
Journal: Cytometry. Part B, Clinical cytometry
Published: May 03, 2020
Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
Journal: Journal for immunotherapy of cancer
Published: April 20, 2020
Utility of CD36 as a novel addition to the immunophenotypic signature of RAM-phenotype acute myeloid leukemia and study of its clinicopathological characteristics.
Journal: Cytometry. Part B, Clinical cytometry
Published: April 08, 2020
Mast cell differentiation of leukemic blasts in diverse myeloid neoplasms: A potential pre-myelomastocytic leukemia condition.
Journal: Cytometry. Part B, Clinical cytometry
Published: March 04, 2020
CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
Journal: Cytometry. Part B, Clinical cytometry
Published: October 06, 2019
Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia-Real-World Context.
Journal: Frontiers in oncology
Published: March 05, 2019
A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-106 and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients.
Journal: Cytometry. Part B, Clinical cytometry
Published: March 02, 2019
Correction: Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia.
Journal: Oncotarget
Published: February 08, 2019
Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia.
Journal: Oncotarget
Published: April 16, 2018
Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies.
Journal: Cytometry. Part B, Clinical cytometry
Published: May 06, 2017
Last Updated: 09/26/2026